Pfizer’s phase 3 Duchenne muscular dystrophy (DMD) gene therapy failure has blown a $230 million hole in the New York pharma’s second quarter financials (PDF). The drugmaker disclosed the discontinuation of the candidate—and the financial fallout—alongside the axing of a respiratory syncytial virus (RSV) combination vaccine.

BioNTech has posted an early win for BNT111, linking a combination of the cancer immunotherapy candidate and Regeneron’s checkpoint inhibitor Libtayo to a better response rate than a historical control in melanoma patients.

Boehringer Ingelheim is offering up to $1.3 billion for Nerio Therapeutics and a preclinical immune checkpoint inhibitor program that the German pharma giant hopes will become the “centerpiece” of its immune-oncology portfolio.

With venture investments pouring into biopharma, steady M&A deals and an increasingly widening IPO market, J.P. Morgan sees the industry returning to growth—finally.

The FDA has placed vTv Therapeutics’ phase 3 trial for cadisegliatin on hold more than two years after the biotech stacked its remaining chips on the Type 1 diabetes drug.

NewAmsterdam Pharma’s drug reduced cholesterol in patients with a genetic disorder by 41% at Week 52, confirming the therapy’s efficacy but falling outside of the range shown in a previous study.

Earlier this month, Flagship Pioneering hinted that another Big Pharma may soon join its growing fleet of collaborators. Now, GSK has sailed into view.

Dexcom’s stock slid by about 40% following its second-quarter earnings report after the diabetes sensor maker said it saw not only fewer customers but also fewer dollars per customer—driving revenue below expectations and the company’s “high standards” both in the U.S. and internationally.

Chemomab Therapeutics has shared phase 2 results it claims show CM-101 is a triple threat in primary sclerosing cholangitis (PSC), simultaneously tackling fibrosis, inflammation and cholestasis. But the pitch fell flat with investors, who sent the biotech’s stock down around 18% when the market opened.

Just over a month after announcing its new Clinical Data Studio, Medidata has its first big customer. Eisai announced July 25 that it is incorporating Medidata’s data studio into its clinical trial management platform.